China Pharma Holdings (CPHI) Change in Account Payables (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly Change in Account Payables came in at -$67771.0 in Q1 2026, down 120.99% YoY from $322935.0 in Q1 2025, and down 123.19% on a QoQ basis from $292259.0 in Q4 2025.
China Pharma Holdings (CPHI) Change in Account Payables (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 17 years of Change in Account Payables data on file, last reported at -$67771.0 in Q1 2026.
- Quarterly Change in Account Payables fell 120.99% year-over-year to -$67771.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $259603.0 (up 374.97% YoY) and the FY2025 annual result came in at $650309.0, up 188.61% from the prior year.
- Change in Account Payables declined to -$67771.0 in Q1 2026, from $292259.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $442807.0 in Q3 2023 to a low of -$505339.0 in Q2 2024.
- A 5-year average of -$1592.2 and a median of $54437.0 in 2025 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2023 — Change in Account Payables surged 3045.77% — and 2024, when it slumped 414.87%.
- Tracing CPHI's Change in Account Payables over 5 years: stood at $238485.0 in 2022, then slumped by 54.75% to $107922.0 in 2023, then slumped by 244.32% to -$155753.0 in 2024, then jumped by 287.64% to $292259.0 in 2025, then plunged by 123.19% to -$67771.0 in 2026.
- The last three Change in Account Payables figures came in at -$67771.0 (Q1 2026), $292259.0 (Q4 2025), and $54437.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | -53.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -143.74 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -21.20 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | China Pharma Holdings | 42.14 Mn | 41.84 Mn | 83,566.00 | -115,563.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -67,771.00 |
| Mar 31, 2026 | -67,771.00 |
| Dec 31, 2025 | 292,259.00 |
| Dec 31, 2025 | 292,259.00 |
| Sep 30, 2025 | 54,437.00 |
| Sep 30, 2025 | 54,437.00 |
| Jun 30, 2025 | -19,322.00 |
| Jun 30, 2025 | -19,322.00 |
| Mar 31, 2025 | 322,935.00 |
| Mar 31, 2025 | 322,935.00 |
| Dec 31, 2024 | -155,753.00 |
| Dec 31, 2024 | -155,753.00 |
| Sep 30, 2024 | 243,744.00 |
| Sep 30, 2024 | 243,744.00 |
| Jun 30, 2024 | -505,339.00 |
| Jun 30, 2024 | -505,339.00 |
| Mar 31, 2024 | -316,568.00 |
| Mar 31, 2024 | -316,568.00 |
| Dec 31, 2023 | 107,922.00 |
| Dec 31, 2023 | 107,922.00 |